Myositis: Clinical Trials

26 trials for Myositis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 recruiting, 5 not yet recruiting, 4 unknown, 3 completed. 26 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 126Recruiting 7, Not yet recruiting 5, Unknown 4, Completed 3, Suspended 2, Terminated 2, Withdrawn 2, Active not recruiting 1

Follow Myositis: new trials by email Literature Review of Myositis trials Research Report on Myositis

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
RD06-05 CAR-T Cell Injection - SLE - Systemic Lupus Erythematosus, Systemic Sclerosis
Early Phase 1Not yet recruitingNanjing Bioheng Biotech Co., Ltd.302026-09-012026-07-16
A Study of BEN301 Injection in theTreatment of Autoimmune Diseases
Single administration of 1x10^8 viable CD4+ CAR+ Foxp3+ cells., Single administration of 3x10^8 viable CD4+ CAR+ Foxp3+ cells. - Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
Early Phase 1SuspendedRenJi Hospital242026-04-202026-06-04
MTS109 in Patients With Refractory Autoimmune Diseases
MTS109 - Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Early Phase 1RecruitingShanghai Changzheng Hospital152026-03-242026-06-30
UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases
UCAR-T cells - Systemic Lupus Erythematosus, Inflammatory Myopathy
Early Phase 1WithdrawnThe Affiliated Hospital of Xuzhou Medical University2026-03-012026-05-28
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
V001-BCMA - Recurrent or Refractory Systemic Lupus Erythematosus, Recurrent or Refractory IgG4 Related Diseases
Early Phase 1Active not recruitingTongji Hospital452025-11-042026-09-17
GC012F Injection in Refractory Idiopathic Inflammatory Myopathy
GC012F Injection infusion - Idiopathic Inflammatory Myopathy (IIM)
Early Phase 1RecruitingDaishi Tian122025-09-152026-01-14
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
CD19/CD22/BCMA CAR-T cells(BZE2204) - Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP)
Early Phase 1RecruitingShanghai Cell Therapy Group Co.,Ltd202025-09-092026-11-12
GC012F in Patients With Autoimmune Diseases
GC012F injection - Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Early Phase 1Not yet recruitingQiong Fu152025-08-182025-07-18
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases
LCAR-AIO T cells - Relapsed/Refractory Autoimmune Diseases
Early Phase 1WithdrawnNanjing Legend Biotech Co.2025-06-172025-07-08
Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
RD06-04 Cell Injection Infusion - Idiopathic Inflammatory Myopathies, ANCA-Associated Vasculitis
Early Phase 1Not yet recruitingPeking University People's Hospital122025-06-142025-05-22
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
UTAA91 injection - Systemic Lupus Erythematosus, Rheumatoid Arthritis
Early Phase 1Not yet recruitingPersonGen BioTherapeutics (Suzhou) Co., Ltd.152025-05-182025-05-14
Safety Study of CC312 in Autoimmune Disease Patients
CC312 - Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
Early Phase 1RecruitingCytoCares Inc182024-11-082025-09-17
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
CD19 or CD19-BCMA CAR-T - SLE (Systemic Lupus), Systemic Sclerosis
Early Phase 1RecruitingNanjing Bioheng Biotech Co., Ltd.202024-09-142026-03-06
Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
RD06-04 CART Cell Injection - Systemic Lupus Erythematosus, Systemic Sclerosis
Early Phase 1SuspendedNanjing Bioheng Biotech Co., Ltd.122024-09-132026-02-03
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
Pozelimab/Cemdisiran - Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
Early Phase 1RecruitingAustin Neuromuscular Center102024-08-082026-01-16
IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy
IMPT-514 CART Cell Injection - Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV)
Early Phase 1TerminatedThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School32024-06-132026-01-28
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
anti-CD19-CAR-T cells - Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Early Phase 1Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical University92024-05-272024-05-17
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
T cell injection targeting CD19 chimeric antigen receptor - Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Early Phase 1UnknownPersonGen BioTherapeutics (Suzhou) Co., Ltd.102024-05-142024-05-16
Characterizing Myositis With 68Ga-FAPI PET/CT
68Ga-FAPI - Myositis, Idiopathic Inflammatory Myopathies
Early Phase 1UnknownThe First Affiliated Hospital of Xiamen University502023-07-012023-07-19
Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases
CD7 CAR T-cells - Crohn Disease, Ulcerative Colitis
Early Phase 1UnknownZhejiang University752022-02-282022-02-15

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Lupus Erythematosus, Systemic (14)  ·  Scleroderma, Systemic (12)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (9)  ·  Autoimmune Diseases (7)  ·  Sjogren's Syndrome (7)  ·  Dermatomyositis (5)  ·  Arthritis, Rheumatoid (4)  ·  Purpura, Thrombocytopenic, Idiopathic (3)  ·  Myositis, Inclusion Body (2)  ·  Recurrence (2)  ·  Anemia, Hemolytic, Autoimmune (1)  ·  Antiphospholipid Syndrome (1)  ·  Arthritis, Juvenile (1)  ·  Autoimmune Diseases of the Nervous System (1)

Broader conditions

Muscular Diseases (26)  ·  Musculoskeletal Diseases (26)  ·  Nervous System Diseases (26)  ·  Neuromuscular Diseases (26)  ·  Skin and Connective Tissue Diseases (21)  ·  Connective Tissue Diseases (20)  ·  Skin Diseases (19)  ·  Immune System Diseases (18)  ·  Autoimmune Diseases (11)  ·  Arthritis (10)  ·  Cardiovascular Diseases (10)  ·  Joint Diseases (10)  ·  Rheumatic Diseases (10)  ·  Skin Diseases, Vascular (10)  ·  Vascular Diseases (10)

Interventions

68Ga-FAPI (1)  ·  Abatacept (1)  ·  Antigens, CD19 (1)  ·  Cyclophosphamide (1)  ·  Etanercept (1)  ·  Fluid Therapy (1)  ·  Hizentra (1)  ·  Immunoglobulins (1)  ·  Therapeutics (1)  ·  fludarabine (1)

Sponsors

Nanjing Bioheng Biotech Co., Ltd. (3)  ·  PersonGen BioTherapeutics (Suzhou) Co., Ltd. (2)  ·  Tongji Hospital (2)  ·  Austin Neuromuscular Center (1)  ·  CytoCares Inc (1)  ·  Daishi Tian (1)  ·  First Affiliated Hospital of Wenzhou Medical University (1)  ·  Nanjing Legend Biotech Co. (1)  ·  Peking University People's Hospital (1)  ·  Pontificia Universidad Catolica de Chile (1)  ·  Qiong Fu (1)  ·  RenJi Hospital (1)  ·  Shanghai Cell Therapy Group Co.,Ltd (1)  ·  Shanghai Changzheng Hospital (1)  ·  The Affiliated Hospital of Xuzhou Medical University (1)

Countries

China (19)  ·  United States (4)  ·  Chile (1)

Top investigators

Carl Pepine, MD (1)  ·  Cristian Vera-Kellet, MD (1)  ·  Glenn Lopate, MD (1)  ·  Guixiu Shi, PhD (1)  ·  He Huang, PhD (1)  ·  Jian Wu, Doctor (1)  ·  LI Sun, Master's (1)  ·  Qiong Fu, Doctor (1)  ·  Wei Wang, MD (1)  ·  Yessar Hussain, MD (1)

Results publications

PMID 19819109, PMID 24034070, PMID 32611669, PMID 37658205, PMID 40425008, PMID 41101309